SEARCH

SEARCH BY CITATION

Kersten H, Molden E, Willumsen T, Engedal K, Wyller TB. Higher anticholinergic drug scale (ADS) scores are associated with peripheral but not cognitive markers of cholinergic blockade. Cross sectional data from 21 Norwegian nursing homes. Br J Clin Pharmacol 2013; 75: 842849.

In [1], there were errors published in three places in the manuscript. The details of these errors are published below:

On page 844, n = 35 is incorrect in the sentence below:

The 87 patients finally included were allocated to the ADS subgroups (score 3, n = 35; score 4, n=22; score 5, n= 16; and score ≥ 6, n = 13).

The correct sentence should be published as:

The 87 patients finally included were allocated to the ADS subgroups (score 3, n = 36, score 4, n = 22; score 5, n= 16; and score ≥ 6, n 13).

On page 844, in Figure 1, there were 40 patients who were physically incapable of executing the tests instead of 44. The correct figure is published below:

figure

Figure 1. Selection of study population. ADS, anticholinergic drug scale; CDR, clinical dementia rating scale

Download figure to PowerPoint

On page 847, in Table 3, the CI of the adjusted mean difference (B) of the salivary flow for those with ADS score ≥ 6 should be corrected to (−0.7, −01) in row 5, column 10. The corrected version of Table 3 is published below.

Table 3. Analysis of covariance to compare the mean differences in anticholinergic end points between the different subgroups of ADS score with reference to ADS score = 3
End pointsADS = 3 referenceADS = 4ADS = 5ADS ≥ 6
Mean (SD)nB (95% CI)nB (95% CI)nB (95% CI)n
UnadjustedAdjustedUnadjustedAdjustedUnadjustedAdjusted
  1. Controlled for CDR in the adjusted models; B, estimates of mean difference with reference to ADS score = 3; †Analysis of covariance performed with log-transformed data; ‡Data given as median and interquartile range; CI confidence interval; SD, standard deviation; * < 0.02; **<0.01; only significant P-values shown; ADS, anticholinergic drug score; n, number of subjects in the subgroup completing each test.

CERAD verbal immediate recall, number of words10.9 (4.9)351.0 (−1.7, 3.8)1.3 (−1.1, 3.8)221.5 (−1.6, 4.5)1.0 (−1.8, 3,7)162.7 (−0.69, 6.0)0.2 (−2.9, 3.4)13
CERAD verbal delayed recall, number of words2.5 (2.5)340.5 (−1.4, 1.5)0.2 (−1.1, 1.7)220.3 (−1.5, 1.8)0.1 (−1.4, 1.6)161.0 (−0.9, 2.7)−0.1 (−1.9, 1.6)13
CERAD verbal recognition, number of words6.4 (3.2)26−1.4 (−3.2, 0.5)−1.2 (−3.1, 0.7)17−0.6 (−2.6, 1.5)−0.6 (−2.7, 1.4)130.6 (−1.5, 2.6)0.1 (−2.0, 2.3)13
Mini mental state examination (MMSE)19.5 (5.1)310.6 (−2.2, 3.4)1.1 (−2.9, 2.8)220.5 (−3.1, 3.2)0.1 (−2.9, 2.8)152.1 (−1.2, 5.5)−0.1 (−3.4, 3.1)13
Whole mouth resting salivary flow (g min−1)0.3 (0.1, 0.7)260.0 (−0.2, 0.3)0.0 (−0.3, 0.3)17−0.1 (−0.3, 0.2)−0.1 (−0.3, 0.2)14−0.5** (−0.7, −0.2)−0.4** (−0.7, −0.1)12
Serum anticholinergic activity (SAA) (pmol ml−1 atropine equivalents)3.6 (2.0, 6.5)340.1 (−0.2, 0.3)0.1 (−0.2, 0.3)220.2 (−0.1, 0.4)0.2 (−0.1, 0.4)150.4** (0.1, 0.6)0.3* (0.1, 0.6)12
Barthel's index of activity of daily living (ADL)46.8 (35.9, 57.7)333.6 (−11.42, 18.7)4.5 (−10.5, 19.6)2215.8 (−1.2, 32.9)15.67 (−1.3, 32.6)1523.18* (4.7, 41.6)19.11 (−0.2, 30.4)12

Reference

  1. Top of page
  2. Reference
  • 1
    Kersten H, Molden E, Willumsen T, Engedal K, Wyller TB. Higher anticholinergic drug scale (ADS) scores are associated with peripheral but not cognitive markers of cholinergic blockade. Cross sectional data from 21 Norwegian nursing homes. Br J Clin Pharmacol 2013; 75: 842849.